CCC Diagnostics, Inc to Present Breast Cancer Study Results at Paris Conference

CCC Diagnostics, in present data describing expanded clinical studies of the DirectHit® Panel for Breast Cancer at the 2nd Worldwide Innovative Networking (WIN) in personalized cancer medicine conference on July 7, 2010 in Paris, France.

June 09, 2010 - CCC Diagnostics, in conjunction with Dr. Katherine Tkaczuk of the University of Maryland Greenebaum Cancer Center, will present data describing expanded clinical studies of the DirectHit® Panel for Breast Cancer at the 2nd Worldwide Innovative Networking (WIN) in personalized cancer medicine conference on July 7, 2010 in Paris, France. The data being presented at WIN will show that DirectHit can predict the responsiveness of late stage breast cancer patients to two additional classes of chemotherapy drugs, taxanes and 5-FU, with a high degree of accuracy

"The data presented at WIN supports our position that The DirectHit® Test Panel for Breast Cancer allows a new approach to drug selection" said John Hughes, President and CEO of CCC Diagnostics. "The information provided by this test supplies crucial information to aid the physician in selecting an effective drug regimen for the individual breast cancer patient."


Categories: Research

Tags: biomarkers, brast cancer, diagnostics


About CCC Diagnostics Inc

View Website

Scott Deamond
CCC Diagnostics Inc

410-633-4885 x1071
CCC Diagnostics Inc
3918 Vero Rd Suite B
Baltimore MD
21227